AUTHORS

Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at http://www.bretjenseninvests.com. Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

2 Reasons Why We Are Seeing These Huge Daily Market Moves

And how to position your portfolio to minimize the impact.

Check Into This Hotel REIT and Try This Underwear Maker on for Size

Chatham Lodging Trust and HanesBrands offer nice payouts while waiting out the current market storm.

After Many Big Misses, an Arrogant Fed Would Do Well to Show Some Humility

The Federal Reserve definitely is more confident in its forecasts than it should be based on its track record over the last decade.

Insiders Are Bellying Up to the Bar for These Names

Entercom Communications, W.R. Grace, Newmark Group and a few airlines are seeing insider purchases.

3 Cheap Building Material Stocks That Insiders Are Buying

Bad news appears fully priced into these equities.

Here's a Handful of Small Biotechs Where Insiders Are Buying

Quotient Limited, Iovance Biotherapeutics and AVEO Pharmaceuticals are among the names seeing insider purchases.

Here Are 3 Small-Cap Names for Biotech Investors to Consider

We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.

3 Profitable Small Biotech Names to Consider

Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.

A Way to Exploit Algorithm-Induced Market Swings When Trading Biotech Issues

It can be disturbing to see various names lose value quickly on no news, but here is a method to take advantage of such moves.

Tuesday Felt Like a Knee Jerk Selloff

Will cooler heads prevail Thursday after investors have had an extra day to reassess the actual situation?

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight